Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
暂无分享,去创建一个
Gil Mor | Sean P. Orton | G. Mor | A. Alvero | N. Sumi | Ayesha Alvero | J. Holmberg | J. Pizzonia | W. Joo | John Pizzonia | Natalia J. Sumi | Eydis Lima | Vinicius Craveiro | Wonduk Joo | Jennie C. Holmberg | Marta Gurrea | Yang Yang-Hartwich | M. Gurrea | Y. Yang-Hartwich | V. Craveiro | E. Lima | S. Orton
[1] J. Rao,et al. Fluorescence imaging in vivo: recent advances. , 2007, Current opinion in biotechnology.
[2] R. Chen,et al. NV‐128, a novel isoflavone derivative, induces caspase‐independent cell death through the Akt/mammalian target of rapamycin pathway , 2009, Cancer.
[3] O. Lapaire,et al. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging , 2014, Archives of Gynecology and Obstetrics.
[4] G. Mor,et al. Multimodality Animal Rotation Imaging System (MARS) for In Vivo Detection of Intraperitoneal Tumors , 2012, American journal of reproductive immunology.
[5] M. de Jong,et al. Of Mice and Humans: Are They the Same?—Implications in Cancer Translational Research , 2010, Journal of Nuclear Medicine.
[6] G. Mor,et al. Stem‐Like Ovarian Cancer Cells Can Serve as Tumor Vascular Progenitors , 2009, Stem cells.
[7] Kathleen R. Cho,et al. Ovarian cancer update: lessons from morphology, molecules, and mice. , 2009, Archives of pathology & laboratory medicine.
[8] G. Mor,et al. Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer , 2011, Journal of oncology.
[9] G. Mor,et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment , 2013, Cancer Medicine.
[10] D. Bergstrom,et al. Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume , 2014, Clinical Cancer Research.
[11] R. Chen,et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance , 2009, Cell cycle.
[12] O. Cj,et al. Frontiers in oncology. , 1990 .
[13] Shengjie Li,et al. Recent Advances , 2018, Journal of Optimization Theory and Applications.
[14] M. Broggini,et al. Revisiting ovarian cancer preclinical models: implications for a better management of the disease. , 2013, Cancer treatment reviews.
[15] C. Annunziata,et al. Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer , 2014, Front. Oncol..
[16] C. Allen,et al. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer , 2008, Molecular Cancer Therapeutics.
[17] D. Rimm,et al. High Frequency of Putative Ovarian Cancer Stem Cells With CD44/CK19 Coexpression Is Associated With Decreased Progression-Free Intervals In Patients With Recurrent Epithelial Ovarian Cancer , 2013, Reproductive Sciences.
[18] R. Kutner,et al. Production of Lentiviral Vectors in Protein‐free Media , 2011, Current protocols in cell biology.
[19] Casey Weaver,et al. Noninvasive bioluminescence imaging in small animals. , 2008, ILAR journal.
[20] Kathleen R. Cho,et al. Lessons From Morphology, Molecules, and Mice , 2009 .
[21] C. Contag,et al. Advances in in vivo bioluminescence imaging of gene expression. , 2002, Annual review of biomedical engineering.
[22] S. Langdon. Animal modeling of cancer pathology and studying tumor response to therapy. , 2012, Current drug targets.
[23] S. Nuti,et al. Constitutive Proteasomal Degradation of TWIST-1 in Epithelial Ovarian Cancer Stem Cells Impacts Differentiation and Metastatic Potential , 2012, Oncogene.
[24] G. Mor,et al. TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence , 2013, Cell cycle.
[25] J. Hickson. In vivo optical imaging: preclinical applications and considerations. , 2009, Urologic oncology.
[26] J. Richards,et al. Minireview: animal models and mechanisms of ovarian cancer development. , 2012, Endocrinology.